Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
25.12
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for MIRM stock have an average target of 54, with a low estimate of 37 and a high estimate of 72. The average target predicts an increase of 114.97% from the current stock price of 25.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MIRM stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
Buy | 4 | 7 | 7 | 6 | 6 | 7 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 9 | 9 | 8 | 8 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Leerink Partners | Leerink Partners | Buy Maintains $44 → $43 | Buy | Maintains | $44 → $43 | +71.18% | Mar 18, 2024 |
JMP Securities | JMP Securities | Buy Maintains $69 → $72 | Buy | Maintains | $69 → $72 | +186.62% | Mar 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $58 | Strong Buy | Maintains | $45 → $58 | +130.89% | Mar 14, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +59.24% | Mar 4, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $58 → $45 | Strong Buy | Maintains | $58 → $45 | +79.14% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
322.45M
from 186.37M
Increased by 73.01%
Revenue Next Year
431.50M
from 322.45M
Increased by 33.82%
EPS This Year
-0.60
from -4.00
EPS Next Year
0.90
from -0.60
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 345.2M | 534.9M | 779.2M | 1.1B | 1.3B |
Avg | 322.5M | 431.5M | 562.8M | 737.2M | 886.4M |
Low | 302.8M | 370.4M | 416.5M | 591.9M | 634.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 85.2% | 65.9% | 80.6% | 87.1% | 77.6% |
Avg | 73.0% | 33.8% | 30.4% | 31.0% | 20.2% |
Low | 62.5% | 14.9% | -3.5% | 5.2% | -14.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 0.50 | 3.33 | 7.17 | 10.19 | 13.31 |
Avg | -0.60 | 0.90 | 2.92 | 6.81 | 8.83 |
Low | -2.43 | -0.88 | -1.20 | 3.59 | 4.55 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 696.8% | 249.0% | 95.4% |
Avg | - | - | 224.2% | 133.5% | 29.6% |
Low | - | - | - | 22.9% | -33.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.